Pill Identifier App

Generic Evista Availability

Evista is a brand name of raloxifene, approved by the FDA in the following formulation(s):

EVISTA (raloxifene hydrochloride - tablet; oral)

  • Manufacturer: LILLY
    Approval date: December 9, 1997
    Strength(s): 60MG [RLD]

Has a generic version of Evista been approved?

No. There is currently no therapeutically equivalent version of Evista available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Evista. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods for inhibiting bone loss
    Patent 5,393,763
    Issued: February 28, 1995
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
    Patent expiration dates:
    • July 28, 2012
      ✓ 
      Patent use: USE FOR INHIBITING BONE RESORPTION
      ✓ 
      Sponsor has requested patent be delisted
  • Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylime thanone hydrochloride
    Patent 5,457,117
    Issued: October 10, 1995
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)thien-3-yl-4[2-(piperidin-1-ethoxyph enol]methanone hydrochloride.
    Patent expiration dates:
    • July 28, 2012
      ✓ 
      Patent use: USE FOR INHIBITING BONE RESORPTION
      ✓ 
      Sponsor has requested patent be delisted
  • Methods of use for inhibiting bone loss and lowering serum cholesterol
    Patent 5,478,847
    Issued: December 26, 1995
    Inventor(s): Draper; Michael W.
    Assignee(s): Eli Lilly and Company
    A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula ##STR1## or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompased by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
    Patent expiration dates:
    • March 2, 2014
      ✓ 
      Patent use: USE FOR INHIBITING BONE RESORPTION
      ✓ 
      Sponsor has requested patent be delisted
  • Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
    Patent 5,811,120
    Issued: September 22, 1998
    Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
    Assignee(s): Eli Lilly and Company
    This invention provides solid orally administerable pharmaceutical formulations comprising raloxifene hydrochloride, a surfactant being sorbitan fatty acid ester or a polyoxyethylene sorbitan fatty acid ester, polyvinylpyrrolidone, and a water soluble diluent which is polyol or sugar.
    Patent expiration dates:
    • March 2, 2014
  • Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
    Patent 5,972,383
    Issued: October 26, 1999
    Inventor(s): Gibson; Lowell L. & Hartauer; Kerry J. & Stowers; Julian L. & Sweetana; Stephanie A. & Thakkar; Arvind L.
    Assignee(s): Eli Lilly and Company
    This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.
    Patent expiration dates:
    • March 2, 2014
      ✓ 
      Patent use: TREATMENT OR PREVENTION OF OSTEOPOROSIS
  • Benzothiophenes formulations containing same and methods
    Patent 6,458,811
    Issued: October 1, 2002
    Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Patent use: USE FOR PREVENTION OF BREAST CANCER
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Benzothiophenes, formulations containing same, and methods
    Patent 6,797,719
    Issued: September 28, 2004
    Inventor(s): Gordon Nelson; Arbuthnot & Brian Weston; Dalder & Kerry John; Hartauer & Wayne Douglas; Luke & Robert Eugene; Stratford, Jr.
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Drug product
  • Benzothiophenes, formulations containing same, and methods
    Patent 6,894,064
    Issued: May 17, 2005
    Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
      ✓ 
      Drug product
  • Methods for inhibiting bone loss
    Patent 6,906,086
    Issued: June 14, 2005
    Inventor(s): Black; Larry J.
    Assignee(s): Eli Lilly and Company
    The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
    Patent expiration dates:
    • July 28, 2012
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    • July 28, 2012
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  • Benzothiophenes, formulations containing same, and methods
    Patent 8,030,330
    Issued: October 4, 2011
    Inventor(s): Arbuthnot; Gordon Nelson & Dalder; Brian Weston & Hartauer; Kerry John & Luke; Wayne Douglas & Stratford, Jr.; Robert Eugene
    Assignee(s): Eli Lilly and Company
    This invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof, characterized that the compound is in particulate form and having a specific size range. The present invention further provides pharmaceutical compositions containing or formulated using compounds of formula I, and the use of such compounds for alleviating human pathologies, including osteoporosis, serum lipid lowering, and breast cancer.
    Patent expiration dates:
    • March 10, 2017
      ✓ 
      Drug product
  • Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
    Patent RE38968
    Issued: February 7, 2006
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)-thien-3-yl-4[2-piperidin-1-ethoxyphenol]methanone hydrochloride.
    Patent expiration dates:
    • July 28, 2012
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    • July 28, 2012
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  • Methods for inhibiting bone loss
    Patent RE39049
    Issued: March 28, 2006
    Inventor(s): Black; Larry J. & Cullinan; George J.
    Assignee(s): Eli Lilly and Company
    The current invention provides methods and pharmaceutical formulations that are useful for inhibiting the loss of bone. These methods and formulations can be used without the associated adverse effects of estrogen therapy, and thus serve as an effective and acceptable treatment for osteoporosis.
    Patent expiration dates:
    • July 28, 2012
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    • July 28, 2012
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
  • Methods of use for inhibiting bone loss and lowering serum cholesterol
    Patent RE39050
    Issued: March 28, 2006
    Inventor(s): Draper; Michael W. & Black; Larry J.
    Assignee(s): Eli Lilly and Company
    A method of inhibiting bone loss or resorption, or lowering serum cholesterol, comprising administering to a human in need thereof a compound having the formula or a pharmaceutically acceptable salt or solvate thereof, in a low dosage amount. Also encompassed by the invention is a a pharmaceutical formulation in unit dosage form comprising, per unit dosage, a low dosage amount.
    Patent expiration dates:
    • March 2, 2014
      ✓ 
      Patent use: PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
    • March 2, 2014
      ✓ 
      Patent use: TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 13, 2014 - ORPHAN DRUG EXCLUSIVITY

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Advertisement
Close

Recommended

(web4)